Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Vorinostat

  • Victoria M. Richon
  • Valeria R. Fantin
  • Justin L. Ricker
  • Stanley R. Frankel
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_6221-2

Synonyms

Definition

Vorinostat is a small-molecule (MW 264) inhibitor of histone deacetylase (HDAC) activity (see Fig. 1).

Keywords

Vascular Endothelial Growth Factor Papillary Thyroid Carcinoma Histone Acetylation Adverse Experience Suberoylanilide Hydroxamic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Johnstone RW (2004) Suberanilohydroxamic acid. Aton Pharma. IDrugs 7:674–682PubMedGoogle Scholar
  2. Marks PA, Rifkind RA, Richon VM et al (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194–202CrossRefPubMedGoogle Scholar
  3. Olsen EA, Kim YH, Kuzel TM et al (2007) Phase IIb multicenter trial of vorinostat in patients with persistent, progressive or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25:3109–3115CrossRefPubMedGoogle Scholar
  4. Richon VM (2006) Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br J Cancer 95(Suppl 1):S2–S6CrossRefPubMedCentralGoogle Scholar
  5. Zolinza™ (vorinostat) (2006) Capsules package insert. Revised Oct 2006. http://www.merck.com/product/usa/pi_circulars/z/zolinza/zolinza_pi.pdf

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Victoria M. Richon
    • 1
  • Valeria R. Fantin
    • 1
  • Justin L. Ricker
    • 1
  • Stanley R. Frankel
    • 1
  1. 1.Merck Research LaboratoriesBostonUSA